Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · Journal of Clinical Oncology · 2009 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

New England Journal of Medicine · 2015 · 1.4K citations · Full text

Medicine, Molecular Genetics, Oncology +17

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 939 citations · Full text

Medicine, Oncology, Pharmacology +12